Therapy pattern of bronchodilators in chronic obstructive pulmonary disease (COPD) patients with acute exacerbations

IF 0.5 Q4 EDUCATION, SCIENTIFIC DISCIPLINES Pharmacy Education Pub Date : 2023-10-10 DOI:10.46542/pe.2023.234.224227
Samirah Samirah, Toetik Aryani, Arina Dery Puspitasari, Marisa Anggia Ibrahim, Bunga Izzatul Lutfiyah, Alfian Nur Rasyid
{"title":"Therapy pattern of bronchodilators in chronic obstructive pulmonary disease (COPD) patients with acute exacerbations","authors":"Samirah Samirah, Toetik Aryani, Arina Dery Puspitasari, Marisa Anggia Ibrahim, Bunga Izzatul Lutfiyah, Alfian Nur Rasyid","doi":"10.46542/pe.2023.234.224227","DOIUrl":null,"url":null,"abstract":"Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a worsening condition of acute respiratory symptoms caused by microbial infection, increased air pollution, and fatigue. Objective: This study determines the pattern of bronchodilators in patients with acute exacerbations of COPD. Method: This study was observational, using the health medical records of patients with COPD at the Universitas Airlangga Hospital, Surabaya. It was conducted between January-December 2019 on male patients who received bronchodilator therapy until discharge and were from age 40 and older. Result: A total of 48 patients met the inclusion criteria. The most commonly used bronchodilator therapy for inpatients was the combination of ipratropium bromide/salbutamol sulfate 0.5 mg/2.5 mg through inhalation in 63.64%. The most frequently used bronchodilator for discharge was salbutamol sulfate 2-4 mg orally in 87.50%. Conclusion: Therapy for acute exacerbation of COPD using a combination of ipratropium bromide/salbutamol sulfate as a preventive therapy is in line with the GOLD guidelines.","PeriodicalId":19944,"journal":{"name":"Pharmacy Education","volume":"17 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2023.234.224227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a worsening condition of acute respiratory symptoms caused by microbial infection, increased air pollution, and fatigue. Objective: This study determines the pattern of bronchodilators in patients with acute exacerbations of COPD. Method: This study was observational, using the health medical records of patients with COPD at the Universitas Airlangga Hospital, Surabaya. It was conducted between January-December 2019 on male patients who received bronchodilator therapy until discharge and were from age 40 and older. Result: A total of 48 patients met the inclusion criteria. The most commonly used bronchodilator therapy for inpatients was the combination of ipratropium bromide/salbutamol sulfate 0.5 mg/2.5 mg through inhalation in 63.64%. The most frequently used bronchodilator for discharge was salbutamol sulfate 2-4 mg orally in 87.50%. Conclusion: Therapy for acute exacerbation of COPD using a combination of ipratropium bromide/salbutamol sulfate as a preventive therapy is in line with the GOLD guidelines.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性阻塞性肺疾病(COPD)急性加重期支气管扩张剂的治疗模式
背景:慢性阻塞性肺疾病(COPD)急性加重是由微生物感染、空气污染加剧和疲劳引起的急性呼吸道症状恶化。目的:本研究确定COPD急性加重期患者支气管扩张剂的使用模式。方法:本研究采用观察性方法,使用泗水艾尔朗加大学医院COPD患者的健康医疗记录。该研究于2019年1月至12月期间对40岁及以上接受支气管扩张剂治疗直至出院的男性患者进行。结果:48例患者符合纳入标准。住院患者最常用的支气管扩张剂治疗是吸入联合使用异丙托品/硫酸沙丁胺醇0.5 mg/2.5 mg,占63.64%。使用支气管扩张剂最多的是口服硫酸沙丁胺醇2 ~ 4 mg,占87.50%。结论:使用异丙托溴铵/硫酸沙丁胺醇联合预防治疗COPD急性加重符合GOLD指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacy Education
Pharmacy Education EDUCATION, SCIENTIFIC DISCIPLINES-
CiteScore
0.80
自引率
20.00%
发文量
174
期刊介绍: Pharmacy Education journal provides a research, development and evaluation forum for communication between academic teachers, researchers and practitioners in professional and pharmacy education, with an emphasis on new and established teaching and learning methods, new curriculum and syllabus directions, educational outcomes, guidance on structuring courses and assessing achievement, and workforce development. It is a peer-reviewed online open access platform for the dissemination of new ideas in professional pharmacy education and workforce development. Pharmacy Education supports Open Access (OA): free, unrestricted online access to research outputs. Readers are able to access the Journal and individual published articles for free - there are no subscription fees or ''pay per view'' charges. Authors wishing to publish their work in Pharmacy Education do so without incurring any financial costs.
期刊最新文献
Knowledge and perception of pharmacists and patients on the use of radiopharmaceuticals in disease management Design and evaluation of a serious game for teaching nanotechnologies in pharmacy education A Taiwanese pharmacy graduate-oriented questionnaire reveals higher confidence and self-evaluation in Pharm.D. graduates What capabilities are required for facilitators to support student pharmacists effectively during experiential learning (EL) in Scotland? What capabilities are required for facilitators to support student pharmacists effectively during experiential learning (EL) in Scotland? – Part 2
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1